Brazil Threatens To Break Merck’s Efavirenz Patent

Law360, New York (April 26, 2007, 12:00 AM EDT) -- Brazil on Wednesday reportedly threatened to break Merck & Co. Inc.’s patent on HIV/AIDS drug Efavirenz, warning it will tap into India’s generic drug industry if the pharmaceutical giant will not offer the country a lower price for the much-needed medicine.

Health Minister Jose Gomes Temporao on Wednesday identified Efavirenz, an antiretroviral drug used to treat HIV and AIDS, as a "public interest" medicine and gave Merck one week to negotiate a discounted price with the Brazilian government, the Associated Press reported.

If negotiations fail, Brazil...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.